

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
HAI for Pancreatic Mets	A Phase II Trial of Hepatic Artery Infusional Floxuridine with Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases	Treatment	SHORE: Dr. G. Paul Wright	Marianne Morrissey marianne.morrissey@spectrumhealth.org (616) 391-1129
EA2142	Gastroenteropancreatic Neuroendocrine Carcinomas: Advanced G3 Non-Small Cell: Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2185	Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs	Other	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2183	A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2187	EA2187 - A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA8143	A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

EA2176	A Phase III Study of Immune checkpoint inhibition with chemotherapy in treatment-naïve metastatic anal cancer patients	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2197	Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN)- A Randomized Phase II/III Trial	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S2001	Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations.	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A021806	A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AHEP1531	Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2186 (GIANT)	A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

Novocure EF-27	PANOVA 3: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant with Gemcitabine and Nab-paclitaxel	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
Lexicon (Tele-ABC)	A Phase II, Multicenter, Open-label, Safety and Efficacy Study of Xermelo plus First-line Chemotherapy (Cis/Gem) in Patients with Locally Advanced, Unresectable, Recurrent, or Metastatic Biliary Tract Cancer (BTC)	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
QED (PROOF)	A Phase III, Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Cis/Gem (Gemcitabine with Cisplatin) in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
EMERALD 2	A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Durvalumab, Monotherapy or in Combination, with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma who are at High Risk of Recurrence After Curative Hepatic Resection or	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
CP-MGAH22-06 (MAHOGANNY)	A Phase II-III Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com

NAPOLI-3	<p>An Open-label, Randomized, Multi-center, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-Fluorouracil/Leucovorin vs Nab-paclitaxel + Gemcitabine in Subjects who have not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas</p>	Treatment	<p>CHCWM Physician Investigators</p>	<p>CHCWM (616) 954-9800 www.chcwm.com</p>
MK-7902	<p>MK-6482-011 : An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After 1 Prior Anti-PD-1/L1 Combination Regimen. Has experienced disease progression on or after first- or second-line systemic treatment with an anti-PD-1/L1 therapy for locally advanced or metastatic RCC. The anti-PD-1/L1 therapy may have been monotherapy or in combination with other agent(s) such as antiCTLA4 or VEGF-targeted-TKI. The immediately preceding line of treatment has to have been an anti-PD-1/L1 therapy</p>	Treatment	<p>CHCWM Physician Investigators</p>	<p>CHCWM (616) 954-9800 www.chcwm.com</p>
MK-3475	<p>MK-6482-012: An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)</p>	Treatment	<p>CHCWM Physician Investigators</p>	<p>CHCWM (616) 954-9800 www.chcwm.com</p>